HPV in Adolescents
Prevalence of HPV and Intraepithelial Neoplasia Biomarkers in Adolescents
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10330
- HIV-NAT
-
Bangkok, Thailand, 10330
- Department of Pediatrics, Chulalongkorn University
-
Bangkok, Thailand, 10330
- Thai Red Cross - Anonymous Clinc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Perinatally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic acid testing (NAT) at any time and history of maternal HIV infection)
- behaviorally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic acid testing (NAT) at any time after sexual debut without history of maternal HIV infection)
- female with vaginal or receptive anal intercourse with a male OR male with receptive rectal intercourse with another male
- Signed informed consent. Volunteers aged 12-17 years can decide whether they wish for their parents to consent for their participation. Due to the confidential nature of the issues being studied, parental consent may be exempted
Exclusion Criteria:
- Have any conditions that may interfer with subjects' ability to understand and consent to the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Perinatally HIV-infected adolescents
|
|
behaviorally HIV-infected adolescents
|
|
HIV negative adolescents
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HPV infection
Time Frame: 48 weeks
|
Prevalence of cervical and anal HPV infection and of oncogenic subtypes, among perinatally HIV-infected adolescents, behaviorally HIV-infected adolescents, and HIv-negative adolescents
|
48 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
intraepithelial neoplasia
Time Frame: 48 weeks
|
Prevalence of intraepithelial neoplasia among the three study groups and in male and female subjects
|
48 weeks
|
|
E6/E7
Time Frame: 48 weeks
|
Prevalence of detected E6/E7 biomarker among the tree study groups and in male and female subjects. Correlation between detected E6/E7 and presence of HPV infection and/or intraepithelial neoplasia Association between HAART use, CD4 counts, plasma HIV RNA level and HIV clinical staging with HPV infection, intraepithelial neoplasia and E6/E7 detection |
48 weeks
|
|
HPV vaccine
Time Frame: 48 weeks
|
Proportion of adolescents who would benefit from the current preventive vaccine (i.e.
those who have not been infected with oncogenic HPV subtypes 16 and 18)
|
48 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nittaya Phanuphak, MD, Thai Red Cross AIDS Research Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HIV-NAT 139
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.